title: Multicentric Castleman disease presenting with fever.
abstract: Multicentric Castleman disease (MCD) is a rare lymphoproliferative disorder that usually manifests with nonspecific symptoms, including fever and lymphadenopathy. Treatment of pediatric MCD varies greatly. A 21-month-old child was diagnosed with MCD after presenting with fever. He had incomplete response to initial therapy directed at interleukin-6, but improved with subsequent chemotherapy.
authors.affiliation: Division of Pediatric Infectious Diseases, University of Colorado School of Medicine, Aurora, CO. Electronic address: Christiana.Smith@childrenscolorado.org.
authors.forename: Christiana
authors.initials: C
authors.lastname: Smith
authors.affiliation: Division of Pediatric Hematology and Oncology, University of Colorado School of Medicine, Aurora, CO.
authors.forename: Cathy
authors.initials: C
authors.lastname: Lee-Miller
authors.affiliation: Department of Pathology, University of Colorado School of Medicine, Aurora, CO.
authors.forename: Megan K
authors.initials: MK
authors.lastname: Dishop
authors.affiliation: Division of Pediatric Hematology and Oncology, University of Colorado School of Medicine, Aurora, CO.
authors.forename: Carrye
authors.initials: C
authors.lastname: Cost
authors.affiliation: Division of Pediatric Hematology and Oncology, University of Colorado School of Medicine, Aurora, CO.
authors.forename: Michael
authors.initials: M
authors.lastname: Wang
authors.affiliation: Division of Pediatric Infectious Diseases, University of Colorado School of Medicine, Aurora, CO; Center for Global Health, Colorado School of Public Health, Aurora, CO.
authors.forename: Edwin J
authors.initials: EJ
authors.lastname: Asturias
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005871:Castleman Disease / Q000175:diagnosis* / Q000503:physiopathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005334:Fever / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007223:Infant; D015850:Interleukin-6 / Q000378:metabolism; D008198:Lymph Nodes / Q000473:pathology; D008214:Lymphocytes / Q000473:pathology; D008297:Male; D010996:Pleural Effusion / Q000188:drug therapy / Q000209:etiology; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D015850:Interleukin-6; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; C502936:tocilizumab; D011241:Prednisone